Nancy Bower

Regulatory Forum Commentary*

Oliver C. Turner, P. Nambiar, F. Sistare, 2014, Toxicologic pathology.

Nonclinical evaluation of abuse liability of the dual orexin receptor antagonist lemborexant.

D. Gauvin, S. Asakura, M. Moline, 2021, Regulatory toxicology and pharmacology : RTP.

Estradiol Promotion of Size and Number of Hepatic Enzyme-Altered Foci in Rats in the Absence of Cell Proliferation

M. Gallo, K. Reuhl, Nancy Bower, 1996 .

Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation.

R. Weaver, W. Casey, O. Doehr, 2020, Regulatory toxicology and pharmacology : RTP.

Lack of value of juvenile animal toxicity studies for supporting the safety of pediatric oncology phase I trials

P. Andrews, T. Kokate, T. Visalli, 2018, Regulatory toxicology and pharmacology : RTP.

Pharmacokinetics, metabolism and excretion of 14C-monoethyl phthalate (MEP) and 14C-diethyl phthalate (DEP) after single oral and IV administration in the juvenile dog

G. Mannens, T. Aoki, Nancy Bower, 2012, Xenobiotica; the fate of foreign compounds in biological systems.

Evaluation of Therapeutics for Severely Debilitating or Life‐Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development

A. Bello, James Hartke, Mazin Derzi, 2020, Clinical pharmacology and therapeutics.

The Dog as a Second Species for Toxicology Testing Provides Value to Drug Development

J. Vahle, B. Kittel, W. Achanzar, 2022, International journal of toxicology.